1. 毕业设计（论文）的内容和要求
癌症作为目前威胁人类健康的头号杀手，一直是医学药学领域的研究重点。
目前针对癌症的治疗手段主要还是手术与放疗、化疗相结合，但传统的放疗手段和化疗药物如铂类化合物对人体副作用较大，手术治疗也存在着术后复发、转移的风险。
因此，设计并开发高效、低毒，甚至具备肿瘤标记、药物示踪功能的诊疗一体化抗肿瘤药物成为了当今肿瘤治疗领域的研究热点。
2. 参考文献
[1] R L Siegel, K D Miller, et al. A Jemal. Cancer statistics, 2015[J]. CA: Cancer J Clin, 2015, 65, (1): 5-29.[2] M Orditura, G Galizia, V Sforza, et al. Treatment of gastric cancer[J]. World J Gastroentero, 2014, 20, (7): 1635-1649.[3] E J Kang, S A Im, D Y Oh, et al. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival[J]. Gastric cancer, 2013, 16, (4): 581-589.[4] Y J Bang, Y K Kang, W K Kang, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer[J]. Invest New Drug, 2011, 29, (6): 1449-1458.[5] D P Silver, A L Richardson, A C Eklund, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer[J]. J Clin Oncol, 2010, 28, (7): 1145-1153.[6] R S Herbst，et al. Erlotinib in Previously Treated NonSmall-Cell Lung Cancer[J]. New Eng J Med, 2005, 353, (2): 123.[7] E L Sievers, P D Senter.，et al. Antibody-drug conjugates in cancer therapy[J]. Annu Rev Med, 2013, 64: 15-29.[8] H J Broxterman, K J Gotink, H M Verheul.，et al. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib[J]. Drug Resist Update, 2009, 12, (4-5): 114-126.[9] Z Duan, K A Brakora, M V Seiden.，et al.Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells[J]. Mol Cancer Ther, 2004, 3, (7): 833-838.[10] R Chenna，et al. Multiple sequence alignment with the Clustal series of programs[J]. Nucleic Acids Res, 2003, 31, (13): 3497-3500.
以上是毕业论文任务书，课题毕业论文、开题报告、外文翻译、程序设计、图纸设计等资料可联系客服协助查找。
